Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B/myeloid acute bilineal leukemia

Leuk Lymphoma. 2020 Apr;61(4):967-970. doi: 10.1080/10428194.2019.1697813. Epub 2019 Dec 6.

Authors

Affiliations

¹ Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
² Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
³ Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan.
⁴ Department of Regenerative Medicine, Kanazawa Medical University, Kahoku-Gun, Japan.

PMID: 31809628
DOI: 10.1080/10428194.2019.1697813

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acute Disease
Child
Drug Therapy, Combination
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Neoplasm, Residual